HELPLINE
The Mesothelioma Applied Research Foundation today announced a pivotal $850,000 investment in mesothelioma research, nearly tripling the Foundation’s research funding from the previous year. The funding includes three competitive research grants of $250,000 each to support innovative scientific investigations and a $100,000 grant to expand a first-of-its-kind multicenter clinical trial for malignant peritoneal mesothelioma. The Foundation awarded…
For too long, mesothelioma patients have faced limited treatment options. But a groundbreaking development at Stanford Medicine is offering new hope.In March 2026, Dr. Leah Backhus, MD, MPH, performed the first PITAC (pressurized intrathoracic aerosol chemotherapy) procedure for mesothelioma in North America. Working alongside Dr. Byrne Lee from the Department…
For decades, mesothelioma has been widely understood as a disease that primarily affects older men with a history of occupational asbestos exposure. While this remains true in many cases, emerging research is challenging that long-held perception and expanding what both patients and healthcare providers should know about this rare and aggressive cancer. Each year, approximately…
The Mesothelioma Applied Research Foundation announced its latest research grant recipients, awarding a total of $300,000 at the International Symposium on Malignant Mesothelioma in Philadelphia on October 25th. This brings the Foundation’s total funding for mesothelioma research to $12.1 million, thanks to generous donations. If you’d like to support this…
Vivace Therapeutics, a company that develops cancer treatments, announced on July 30, 2025, that the U.S. Food and Drug Administration (FDA) has granted its experimental drug, VT3989, an “Orphan Drug Designation” (ODD) to treat mesothelioma, a rare and aggressive form of cancer.VT3989 is a TEAD inhibitor. It works by blocking…
The Mesothelioma Applied Research Foundation is excited to announce its latest research grant recipients, awarding a total of $300,000. This brings the Foundation’s…
The phase 3 clinical trial known as BEAT-meso, which combines chemotherapy plus bevacizumab with immunotherapy, has shown an improvement in overall survival (OS) and progression-free…
Hair loss, or alopecia, is often associated with cancer therapies and, in particular, with cytotoxic chemotherapy. While this side effect is most often temporary –…
Due to recent advances in cancer treatment, especially in the field of immunotherapy, chemotherapy treatment options for mesothelioma have taken a back seat. However, this…
This article aims to build on the Part 1 of this series. Out of necessity, mesothelioma patients more than other patient groups are savvy consumers…
